section_path: Treatment/Monoclonal antibodies
section_name: Monoclonal antibodies
paragraph_text: Monoclonal antibodies
  
  A 2022 clinical trial shows that a monoclonal antibody mAb L9LS offers protection against malaria. It binds the Plasmodium falciparum circumsporozoite protein (CSP-1), essential to disease, and makes it ineffective.